Sharon Lewin

Lewin began her research career just as an antiretroviral treatment emerged for people living with HIV.{{cn|date=March 2023}} Drawn to study HIV because of its global challenge, along with the complex social issues, Lewin's research interests have developed from questions arising during the clinical care of people living with HIV. Detecting, quantifying and potentially reactivating latent HIV is a central theme of Lewin's research, which spans basic virology, cellular immunology and clinical research. Her research laboratory is run together with immunologist and clinician Paul Cameron.{{cn|date=March 2023}}

While completing her postdoctoral training with David Ho at the Aaron Diamond AIDS Research Centre, Lewin developed a highly sensitive PCR method to detect unspliced HIV RNA, an early product of viral transcription, in people receiving antiretroviral drugs.{{Cite journal|last1=Lewin|first1=S. R.|last2=Vesanen|first2=M.|last3=Kostrikis|first3=L.|last4=Hurley|first4=A.|last5=Duran|first5=M.|last6=Zhang|first6=L.|last7=Ho|first7=D. D.|last8=Markowitz|first8=M.|date=July 1999|title=Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy|journal=Journal of Virology|volume=73|issue=7|pages=6099–6103|issn=0022-538X|pmc=112674|pmid=10364365|doi=10.1128/JVI.73.7.6099-6103.1999}} Lewin's laboratory has developed models of HIV latency which are used to further tease out the mechanisms involved, and to assess the impact of latency reversal agents.{{cn|date=November 2023}} Lewin's lab has shown that triggering the CCR7 receptor on resting CD4 T cells can induce latency,{{Cite journal|last1=Saleh|first1=Suha|last2=Solomon|first2=Ajantha|last3=Wightman|first3=Fiona|last4=Xhilaga|first4=Miranda|last5=Cameron|first5=Paul U.|last6=Lewin|first6=Sharon R.|date=2007-12-15|title=CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency|journal=Blood|language=en|volume=110|issue=13|pages=4161–4164|doi=10.1182/blood-2007-06-097907|issn=0006-4971|pmid=17881634|doi-access=free}} acting through the activation of the cellular cytoskeleton, particularly actin remodelling.{{Cite journal|last1=Cameron|first1=Paul U.|last2=Saleh|first2=Suha|last3=Sallmann|first3=Georgina|last4=Solomon|first4=Ajantha|last5=Wightman|first5=Fiona|last6=Evans|first6=Vanessa A.|last7=Boucher|first7=Genevieve|last8=Haddad|first8=Elias K.|last9=Sekaly|first9=Rafick-Pierre|date=2010-09-28|title=Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton|journal=Proceedings of the National Academy of Sciences|language=en|volume=107|issue=39|pages=16934–16939|doi=10.1073/pnas.1002894107|issn=0027-8424|pmid=20837531|pmc=2947912|bibcode=2010PNAS..10716934C|doi-access=free}} This chemokine-induced latency model has been used in a comprehensive comparison of in vitro models for evaluating latency reversal agents.{{Cite journal|last1=Spina|first1=Celsa A.|last2=Anderson|first2=Jenny|last3=Archin|first3=Nancie M.|last4=Bosque|first4=Alberto|last5=Chan|first5=Jonathan|last6=Famiglietti|first6=Marylinda|last7=Greene|first7=Warner C.|last8=Kashuba|first8=Angela|last9=Lewin|first9=Sharon R.|date=2013-12-26|title=An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients|journal=PLOS Pathogens|volume=9|issue=12|pages=e1003834|doi=10.1371/journal.ppat.1003834|pmid=24385908|pmc=3873446|issn=1553-7374 |doi-access=free }} Lewin's laboratory has also described the role of myeloid dendritic cells{{Cite journal|last1=Evans|first1=Vanessa A.|last2=Kumar|first2=Nitasha|last3=Filali|first3=Ali|last4=Procopio|first4=Francesco A.|last5=Yegorov|first5=Oleg|last6=Goulet|first6=Jean-Philippe|last7=Saleh|first7=Suha|last8=Haddad|first8=Elias K.|last9=Pereira|first9=Candida da Fonseca|date=2013-12-05|title=Myeloid Dendritic Cells Induce HIV-1 Latency in Non-proliferating CD4+ T Cells|journal=PLOS Pathogens|volume=9|issue=12|pages=e1003799|doi=10.1371/journal.ppat.1003799|pmid=24339779|issn=1553-7374|pmc=3855553 |doi-access=free }} and other antigen-presenting cells{{Cite journal|last1=Kumar|first1=Nitasha A.|last2=Cheong|first2=Karey|last3=Powell|first3=David R.|last4=da Fonseca Pereira|first4=Candida|last5=Anderson|first5=Jenny|last6=Evans|first6=Vanessa A.|last7=Lewin|first7=Sharon R.|last8=Cameron|first8=Paul U.|date=2015-09-11|title=The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells|journal=Retrovirology|volume=12|pages=76|doi=10.1186/s12977-015-0204-2|pmid=26362311|issn=1742-4690|pmc=4567795 |doi-access=free }} in establishing HIV latency.

Lewin's team have made contributions to the knowledge of the HIV reservoir during antiretroviral treatment. This includes studies of naive CD4 T cells, where longitudinal and cross-sectional studies have shown that both CD31+ and CD31- naive CD4 T cells contribute to the ongoing HIV reservoir{{Cite journal|last1=Wightman|first1=Fiona|last2=Solomon|first2=Ajantha|last3=Khoury|first3=Gabriela|last4=Green|first4=Justin A.|last5=Gray|first5=Lachlan|last6=Gorry|first6=Paul R.|last7=Ho|first7=Yung Shwen|last8=Saksena|first8=Nitin K.|last9=Hoy|first9=Jennifer|date=2010-12-01|title=Both CD31+ and CD31- Naive CD4+ T Cells Are Persistent HIV Type 1-Infected Reservoirs in Individuals Receiving Antiretroviral Therapy|journal=The Journal of Infectious Diseases|volume=202|issue=11|pages=1738–1748|doi=10.1086/656721|pmid=20979453|issn=0022-1899|doi-access=free}} and that HIV DNA is preferentially found in CD4 T cells expressing the chemokine receptors CXCR3 and CCR6.{{Cite journal|last1=Khoury|first1=Gabriela|last2=Anderson|first2=Jenny L.|last3=Fromentin|first3=Rémi|last4=Hartogenesis|first4=Wendy|last5=Smith|first5=Miranda Z.|last6=Bacchetti|first6=Peter|last7=Hecht|first7=Frederick M.|last8=Chomont|first8=Nicolas|last9=Cameron|first9=Paul U.|date=2016-06-19|title=Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy|journal=AIDS|language=ENGLISH|volume=30|issue=10|pages=1511–1520|doi=10.1097/qad.0000000000001029|pmid=26807971|pmc=4889535|issn=0269-9370}} Lewin's group has also studied immune reconstitution after antiretroviral treatment begins, exposing some of the factors associated with faster reconstitution{{Cite journal|last1=Rajasuriar|first1=Reena|last2=Gouillou|first2=Maelenn|last3=Spelman|first3=Tim|last4=Read|first4=Tim|last5=Hoy|first5=Jennifer|last6=Law|first6=Matthew|last7=Cameron|first7=Paul U.|last8=Petoumenos|first8=Kathy|last9=Lewin|first9=Sharon R.|date=2011-06-02|title=Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database|journal=PLOS ONE|volume=6|issue=6|pages=e20713|doi=10.1371/journal.pone.0020713|pmid=21674057|pmc=3107235|issn=1932-6203|bibcode=2011PLoSO...620713R|doi-access=free}} and has demonstrated a link between immune reconstitution and variants in the IL-7R gene.{{Cite journal|last1=Rajasuriar|first1=R.|last2=Booth|first2=D. R.|last3=Gouillou|first3=M.|last4=Spelman|first4=T.|last5=James|first5=I.|last6=Solomon|first6=A.|last7=Chua|first7=K.|last8=Stewart|first8=G.|last9=Deeks|first9=S.|date=January 2012|title=The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART|journal=Genes and Immunity|language=en|volume=13|issue=1|pages=83–93|doi=10.1038/gene.2011.65|pmid=21938017|issn=1466-4879|doi-access=free}}{{Cite journal|last1=Rajasuriar|first1=Reena|last2=Booth|first2=David|last3=Solomon|first3=Ajantha|last4=Chua|first4=Kyra|last5=Spelman|first5=Tim|last6=Gouillou|first6=Maelenn|last7=Schlub|first7=Timothy E.|last8=Davenport|first8=Miles|last9=Crowe|first9=Suzanne|date=2010-10-15|title=Biological Determinants of Immune Reconstitution in HIV-Infected Patients Receiving Antiretroviral Therapy: The Role of Interleukin 7 and Interleukin 7 Receptor α and Microbial Translocation|journal=The Journal of Infectious Diseases|volume=202|issue=8|pages=1254–1264|doi=10.1086/656369|pmid=20812848|issn=0022-1899|doi-access=free}}

Lewin's research has elucidated some of the basic immunology of Hepatitis B infection alone{{Cite journal|last1=Chang|first1=J. Judy|last2=Thompson|first2=Alexander J. V.|last3=Visvanathan|first3=Kumar|last4=Kent|first4=Stephen J.|last5=Cameron|first5=Paul U.|last6=Wightman|first6=Fiona|last7=Desmond|first7=Paul|last8=Locarnini|first8=Stephen A.|last9=Lewin|first9=Sharon R.|date=2007-11-01|title=The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection|journal=Hepatology|language=en|volume=46|issue=5|pages=1332–1340|doi=10.1002/hep.21844|pmid=17924445|s2cid=9902334|issn=1527-3350|doi-access=free}} and in co-infection with HIV.{{Cite journal|last1=Chang|first1=J. Judy|last2=Wightman|first2=Fiona|last3=Bartholomeusz|first3=Angeline|last4=Ayres|first4=Anna|last5=Kent|first5=Stephen J.|last6=Sasadeusz|first6=Joseph|last7=Lewin|first7=Sharon R.|date=2005-03-01|title=Reduced Hepatitis B Virus (HBV)-Specific CD4+ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy|journal=Journal of Virology|language=en|volume=79|issue=5|pages=3038–3051|doi=10.1128/jvi.79.5.3038-3051.2005|issn=0022-538X|pmid=15709024|pmc=548440}} Ongoing research is providing a deeper understanding of the clinical consequences of co-infection with Hepatitis B and HIV, both in Australian participants{{Cite journal|last1=Lewin|first1=Sharon R.|last2=Ribeiro|first2=Ruy M.|last3=Walters|first3=Tomos|last4=Lau|first4=George K.|last5=Bowden|first5=Scott|last6=Locarnini|first6=Stephen|last7=Perelson|first7=Alan S.|date=2001-11-01|title=Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed|journal=Hepatology|language=en|volume=34|issue=5|pages=1012–1020|doi=10.1053/jhep.2001.28509|pmid=11679973|s2cid=206249432|issn=1527-3350|doi-access=free}}{{Cite journal|last1=Audsley|first1=Jennifer|last2=Robson|first2=Christopher|last3=Aitchison|first3=Stacey|last4=Matthews|first4=Gail V.|last5=Iser|first5=David|last6=Sasadeusz|first6=Joe|last7=Lewin|first7=Sharon R.|date=2016-01-01|title=Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy|journal=Open Forum Infectious Diseases|volume=3|issue=1|pages=ofw035|doi=10.1093/ofid/ofw035|pmid=27006960|pmc=4800457}} and through a long-standing collaboration with Thai researchers.{{Cite journal|last1=Matthews|first1=Gail V.|last2=Avihingsanon|first2=Anchalee|last3=Lewin|first3=Sharon R.|last4=Amin|first4=Janaki|last5=Rerknimitr|first5=Rungsun|last6=Petcharapirat|first6=Panusit|last7=Marks|first7=Pip|last8=Sasadeusz|first8=Joe|last9=Cooper|first9=David A.|date=2008-10-01|title=A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand|journal=Hepatology|language=en|volume=48|issue=4|pages=1062–1069|doi=10.1002/hep.22462|pmid=18697216|issn=1527-3350|doi-access=free}}{{Cite journal|last1=Crane|first1=Megan|last2=Sirivichayakul|first2=Sunee|last3=Chang|first3=J. Judy|last4=Avihingsanon|first4=Anchalee|last5=Ubolyam|first5=Sasiwimol|last6=Buranapraditkun|first6=Supranee|last7=Thantiworasit|first7=Pattarawat|last8=Wightman|first8=Fiona|last9=Locarnini|first9=Stephen|date=2010-03-15|title=No Increase in Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy|journal=Journal of Virology|language=en|volume=84|issue=6|pages=2657–2665|doi=10.1128/jvi.02124-09|issn=0022-538X|pmid=20053751|pmc=2826062}}{{Cite journal|last1=Crane|first1=Megan|last2=Avihingsanon|first2=Anchalee|last3=Rajasuriar|first3=Reena|last4=Velayudham|first4=Pushparaj|last5=Iser|first5=David|last6=Solomon|first6=Ajantha|last7=Sebolao|first7=Baotuti|last8=Tran|first8=Andrew|last9=Spelman|first9=Tim|date=2014-09-01|title=Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV)–Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy|journal=The Journal of Infectious Diseases|volume=210|issue=5|pages=745–751|doi=10.1093/infdis/jiu119|pmid=24585898|issn=0022-1899|doi-access=free}}{{Cite journal|last1=Punyawudho|first1=Baralee|last2=Thammajaruk|first2=Narukjaporn|last3=Thongpeang|first3=Parawee|last4=Matthews|first4=Gail|last5=Lewin|first5=Sharon R.|last6=Burger|first6=David|last7=Ruxrungtham|first7=Kiat|last8=Avihingsanon|first8=Anchalee|title=Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients|journal= International Journal of Clinical Pharmacology and Therapeutics|volume=53|issue=11|pages=947–954|doi=10.5414/cp202386|pmid=26308175|year=2015}}

Lewin's clinical research efforts have focussed on potential HIV cure strategies, particularly those using the epigenetic modifiers including histone deacetylase inhibitors (HDACis).{{Cite journal|last1=Rasmussen|first1=Thomas Aagaard|last2=Søgaard|first2=Ole Schmeltz|last3=Brinkmann|first3=Christel|last4=Wightman|first4=Fiona|last5=Lewin|first5=Sharon R.|last6=Melchjorsen|first6=Jesper|last7=Dinarello|first7=Charles|last8=Østergaard|first8=Lars|last9=Tolstrup|first9=Martin|date=2013-05-14|title=Comparison of HDAC inhibitors in clinical development|journal=Human Vaccines & Immunotherapeutics|volume=9|issue=5|pages=993–1001|doi=10.4161/hv.23800|issn=2164-5515|pmid=23370291|pmc=3899169}}{{Cite journal|last1=Wightman|first1=Fiona|last2=Ellenberg|first2=Paula|last3=Churchill|first3=Melissa|last4=Lewin|first4=Sharon R.|date=January 2012|title=HDAC inhibitors in HIV|journal=Immunology and Cell Biology|language=en|volume=90|issue=1|pages=47–54|doi=10.1038/icb.2011.95|pmid=22083528|s2cid=21811612|issn=0818-9641|doi-access=free}} In vitro experiments showed that HDACis such as entinostat,{{Cite journal|last1=Wightman|first1=Fiona|last2=Lu|first2=Hao K.|last3=Solomon|first3=Ajantha E.|last4=Saleh|first4=Suha|last5=Harman|first5=Andrew N.|last6=Cunningham|first6=Anthony L.|last7=Gray|first7=Lachlan|last8=Churchill|first8=Melissa|last9=Cameron|first9=Paul U.|title=Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells|journal=AIDS|volume=27|issue=18|pages=2853–2862|doi=10.1097/qad.0000000000000067|pmid=24189584|pmc=4079759|year=2013}} metacept-1 and -3{{Cite journal|last1=Shehu-Xhilaga|first1=Miranda|last2=Rhodes|first2=David|last3=Wightman|first3=Fiona|last4=Liu|first4=Hong B|last5=Solomon|first5=Ajantha|last6=Saleh|first6=Suha|last7=Dear|first7=Anthony E|last8=Cameron|first8=Paul U|last9=Lewin|first9=Sharon R|title=The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells|journal=AIDS|volume=23|issue=15|pages=2047–2050|doi=10.1097/qad.0b013e328330342c|pmid=19609198|year=2009|s2cid=39280869|doi-access=free}} could activate latent HIV in primary T cells. Following a sabbatical working with Christine Katlama and Brigitte Autran at the Hopital Pitié-Salpêtrière and Université Pierre et Marie Curie (UPMC), Paris, Lewin began to focus more on moving potential cure strategies into clinical trials.{{Cite journal|last1=Lewin|first1=Sharon R|last2=Rouzioux|first2=Christine|title=HIV cure and eradication: how will we get from the laboratory to effective clinical trials?|journal=AIDS|volume=25|issue=7|pages=885–897|doi=10.1097/qad.0b013e3283467041|pmid=21422987|year=2011|s2cid=23266836|doi-access=free}} Lewin's lab conducted the first multi-dose proof-of-concept HDACi trial in HIV positive participants, administering vorinostat daily over a 14-day period and assessing safety and impact on HIV transcription and reservoirs.{{Cite journal|last1=Elliott|first1=Julian H.|last2=Wightman|first2=Fiona|last3=Solomon|first3=Ajantha|last4=Ghneim|first4=Khader|last5=Ahlers|first5=Jeffrey|last6=Cameron|first6=Mark J.|last7=Smith|first7=Miranda Z.|last8=Spelman|first8=Tim|last9=McMahon|first9=James|date=2014-11-13|title=Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy|journal=PLOS Pathogens|volume=10|issue=11|pages=e1004473|doi=10.1371/journal.ppat.1004473|pmid=25393648|issn=1553-7374|pmc=4231123 |doi-access=free }} The trial and follow-on study{{Cite journal|last1=Mota|first1=Talia M.|last2=Rasmussen|first2=Thomas A.|last3=Rhodes|first3=Ajantha|last4=Tennakoon|first4=Surekha|last5=Dantanarayana|first5=Ashanti|last6=Wightman|first6=Fiona|last7=Hagenauer|first7=Michelle|last8=Roney|first8=Janine|last9=Spelman|first9=Tim|date=2017-05-15|title=No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy|journal=AIDS|language=ENGLISH|volume=31|issue=8|pages=1137–1141|doi=10.1097/qad.0000000000001442|pmid=28301423|pmc=5496768|issn=0269-9370}} showed that while vorinostat was safe and able to increase HIV transcription in most participants, it did not reduce the HIV reservoir. A dose-escalation study conducted in Melbourne, Australia and San Francisco, California, USA of the anti-alcohol compound Disulfiram also showed the ability to increase levels of cell-associated unspliced HIV RNA.{{Cite journal|last1=Elliott|first1=Julian H|last2=McMahon|first2=James H|last3=Chang|first3=Christina C|last4=Lee|first4=Sulggi A|last5=Hartogensis|first5=Wendy|last6=Bumpus|first6=Namandje|last7=Savic|first7=Rada|last8=Roney|first8=Janine|last9=Hoh|first9=Rebecca|title=Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study|journal=The Lancet HIV|volume=2|issue=12|pages=e520–e529|doi=10.1016/s2352-3018(15)00226-x|pmid=26614966|pmc=5108570|year=2015}} Both vorinostat and Disulfiram are now being investigated as part of a combination approach to latency activation ('kick' or 'tickle') followed by a second intervention to remove cells harbouring reactivated virus ('kill' or 'tease').

Lewin gave the opening plenary at the International AIDS Conference in Vienna in 2010.{{cn|date=November 2023}} Lewin was local co-chair for the International AIDS Conference (AIDS 2014) in Melbourne, a member of WHO and UNAIDS strategic advisory groups and lead co-author of the 2016 International AIDS Society global scientific strategy to achieve an HIV cure.{{Cite journal|last1=Deeks|first1=Steven G|last2=Lewin|first2=Sharon R|last3=Ross|first3=Anna Laura|last4=Ananworanich|first4=Jintanat|last5=Benkirane|first5=Monsef|last6=Cannon|first6=Paula|last7=Chomont|first7=Nicolas|last8=Douek|first8=Daniel|last9=Lifson|first9=Jeffrey D|title=International AIDS Society global scientific strategy: towards an HIV cure 2016|journal=Nature Medicine|volume=22|issue=8|pages=839–850|doi=10.1038/nm.4108|pmid=27400264|pmc=5322797|year=2016|hdl=10044/1/45370|url=http://spiral.imperial.ac.uk/bitstream/10044/1/45370/2/Towards%20a%20Cure%20meeting%20summary%20IAS%202015%20JVE.pdf}} Lewin is a founding council member of the Academy of Health and Medical Sciences, elected member of the Governing Council of the International AIDS Society representing the Asia Pacific region, she became President of the International AIDS Society in 2022 for a two-year tenure,{{Cite web |title=Sharon Lewin assumes IAS Presidency |url=https://www.iasociety.org/news-release/sharon-lewin-assumes-ias-presidency |access-date=2023-05-11 |website=www.iasociety.org |language=en}} member of the council of the National Health and Medical Research Council (NHMRC) of Australia and chairs the Health Translation Advisory Committee. She chairs the Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmitted Infections, the peak advisory group to the minister of health of Australia.{{cn|date=March 2023}}

• Peter Wills Medal (2015){{cite web |last1=Natoli |first1=Andrea |title=2015 Peter Wills Medal: Prof Sharon Lewin |url=https://researchaustralia.org/2015-peter-wills-medal-prof-sharon-lewin/ |website=RESEARCH AUSTRALIA |access-date=15 March 2024 |language=en-AU |date=6 April 2016}}
• Officer of the Order of Australia (2019) "For distinguished service to medical research, and to education, in the field of infectious diseases, particularly HIV/AIDS."{{Cite web|url=https://www.gg.gov.au/sites/default/files/files/honours/ad/ad2019/xklw-03mcv/Gazette%20-%20Order%20of%20Australia.pdf|title=Australia Day 2019 Honours List|date=2019-01-26|website=Governor General of the Commonwealth of Australia|access-date=2019-01-27}}
• Victorian Honour Roll of Women (2019){{Cite web |date=2019-03-07 |title=Professor Sharon Lewin AO |url=https://www.vic.gov.au/professor-sharon-lewin-ao |access-date=2025-04-30 |website=State Government of Victoria |language=en-au}}
• Global Virus Network’s (GVN) Robert C. Gallo Award for Scientific Excellence and Leadership in Medical Virology (2020){{cite web |title=Professor Sharon Lewin presented with GVN Robert C Gallo Award |url=https://www.doherty.edu.au/news-events/news/sharon-lewin-presented-with-gvn-robert-c-gallo-award |website=www.doherty.edu.au |publisher=The Doherty Institute |access-date=15 March 2024 |language=en |date=22 September 2020}}
• Melbourne Achiever Award (2020){{cite web |title=Sharon Lewin AO, FRACP PhD FAHMS and RMIT University win 2020 Melbourne Achiever Award |url=https://melbourne.org.au/news/sharon-lewin-ao-fracp-phd-fahms-and-rmit-university-win-2020-melbourne-achiever-award-2/ |website=Committee For Melbourne |access-date=15 March 2024 |language=en-AU}}
• 2020–21 Vocational Service Award (2021){{cite web |title=PROFESSOR SHARON LEWIN AO |url=https://rotaryclubofmelbourne.org.au/news/41112/professor-sharon-lewin-ao/ |website=rotaryclubofmelbourne.org.au |access-date=15 March 2024}}
• Medal for Outstanding Female Researcher from the Australian Academy of Health and Medical Sciences (2022){{cite web |last1=Rowney |first1=Katie |title=Professor Sharon Lewin awarded Medal for Outstanding Female Researcher - AAHMS |url=https://aahms.org/media-release/professor-sharon-lewin-2022-outstanding-female-researcher-medal/ |website=aahms.org |access-date=15 March 2024 |language=en-AU |date=6 September 2022}}
• Fellow of the Australian Academy of Science (2023){{Cite web |title=Sharon Lewin |url=https://www.science.org.au/profile/sharon-lewin |access-date=2023-05-25 |website=www.science.org.au |language=en}}
• Honorary Doctor of Science from La Trobe University (2023){{Cite web|url=https://www.latrobe.edu.au/news/articles/2023/release/la-trobe-awards-hon-docs-to-global-health-pioneers|title=La Trobe awards Hon Docs to global health pioneers|date=2023-10-25|website=La Trobe University|access-date=2023-11-01}}
• Honorary Doctor from University of Bonn (2025){{Cite web|url=https://www.uni-bonn.de/de/neues/023-2025|title=Bonner Medizinische Fakultät verleiht Ehrendoktorwürde an Sharon Lewin|date=2025-02-06|website=University of Bonn|access-date=2025-02-06}}

{{reflist}}

{{Authority control}}

{{DEFAULTSORT:Lewin, Sharon}}

Category:Australian infectious disease physicians

Category:Year of birth missing (living people)

Category:Living people

Category:Scientists from Melbourne

Category:Jewish women scientists

Category:Australian Jews

Category:Fellows of the Australian Academy of Health and Medical Sciences

Category:Officers of the Order of Australia

Category:Fellows of the Australian Academy of Science